Citizens Maintains Market Outperform on Intellia Therapeutics, Raises Price Target to $30

Benzinga Newsdesk www.benzinga.com Positive 92.5%

Neg 0% Neu 0% Pos 92.5%

Citizens analyst Silvan Turkcan maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and raises the price target from $28 to $30.